Wilfred Premila M, Mathew Sumith, Chacko Binila, Prabha Ratna, Mathew Binu Susan
Department of Pharmacology and Clinical Pharmacology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Medical Intensive Care Unit, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Indian J Crit Care Med. 2022 Jun;26(6):682-687. doi: 10.5005/jp-journals-10071-24235.
In critically ill patients with low albumin, dose individualization of phenytoin is a challenge. The currently used Sheiner-Tozer equation does not accurately predict the free phenytoin concentration in serum and can result in incorrect dose modifications. The best measure to advocate in these patients is the direct-measurement of free phenytoin concentration.
Phenytoin exhibits complex pharmacokinetics, requiring careful therapeutic drug monitoring. This study aimed to compare the accuracy of the established Sheiner-Tozer calculation method against the direct-measurement of free phenytoin concentration in serum by high performance liquid chromatography in critically ill patients with low albumin.
Blood specimens for direct-measurement of both total and free phenytoin concentration were obtained from 57 patients with hypoalbuminemia monitored in the intensive care unit.
The median [inter-quartile range (IQR)] for Sheiner-Tozer equation calculated total phenytoin concentration and direct-measured total was 17.14 (10.63-24.53) and 9.82 (6.02-13.85) μg mL, respectively. Approximately 53 and 5% of patients were found to be subtherapeutic and supratherapeutic for direct-measured total phenytoin concentrations, respectively. In contrast, on applying the Sheiner-Tozer calculation, 23 and 40% had subtherapeutic and supratherapeutic concentrations, respectively, for total phenytoin concentration. The median (IQR) for direct-measured, routine and Sheiner-Tozer equation calculated free phenytoin concentration were 1.92 (1.06-2.76), 0.98 (0.60-1.39), and 1.71 (1.06-2.45) μg mL, respectively. Only 45.7% of patients were in agreement with respect to the therapeutic category when direct-measured free was compared against routine calculation free.
In patients with low albumin, free phenytoin concentration based on the Sheiner-Tozer corrected equation accurately classified patients based on their therapeutic category of free phenytoin in 73.7% of patients. Hence, for individualization of phenytoin dosage in critically ill patients with low albumin, we recommend direct-measurement of free phenytoin concentration.
Wilfred PM, Mathew S, Chacko B, Prabha R, Mathew BS. Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations. Indian J Crit Care Med 2022;26(6):682-687.
在白蛋白水平低的危重症患者中,苯妥英钠的剂量个体化是一项挑战。目前使用的谢纳 - 托泽方程不能准确预测血清中游离苯妥英钠的浓度,可能导致剂量调整错误。对于这些患者,最提倡的措施是直接测量游离苯妥英钠浓度。
苯妥英钠具有复杂的药代动力学,需要仔细的治疗药物监测。本研究旨在比较已确立的谢纳 - 托泽计算方法与通过高效液相色谱法直接测量白蛋白水平低的危重症患者血清中游离苯妥英钠浓度的准确性。
从重症监护病房监测的57例低白蛋白血症患者中采集血液样本,用于直接测量总苯妥英钠浓度和游离苯妥英钠浓度。
谢纳 - 托泽方程计算的总苯妥英钠浓度中位数[四分位间距(IQR)]和直接测量的总浓度分别为17.14(10.63 - 24.53)和9.82(6.02 - 13.85)μg/mL。发现分别约有53%和5%的患者直接测量的总苯妥英钠浓度低于治疗水平和高于治疗水平。相比之下,应用谢纳 - 托泽计算法时,总苯妥英钠浓度低于治疗水平和高于治疗水平的患者分别为23%和40%。直接测量的、常规计算的和谢纳 - 托泽方程计算的游离苯妥英钠浓度中位数(IQR)分别为1.92(1.06 - 2.76)、0.98(0.60 - 1.39)和1.71(1.06 - 2.45)μg/mL。当将直接测量的游离苯妥英钠浓度与常规计算的游离苯妥英钠浓度进行比较时,只有45.7%的患者在治疗类别方面一致。
在白蛋白水平低的患者中,基于谢纳 - 托泽校正方程的游离苯妥英钠浓度能在73.7%的患者中根据其游离苯妥英钠的治疗类别准确分类患者。因此,对于白蛋白水平低的危重症患者苯妥英钠剂量的个体化,我们建议直接测量游离苯妥英钠浓度。
威尔弗雷德·P·M,马修·S,查科·B,普拉巴·R,马修·B·S。低白蛋白血症危重症患者游离苯妥英钠浓度的估计:直接测量与传统方程。《印度重症监护医学杂志》2022;26(6):682 - 687。